Curie.Bio

We built Curie.Bio to provide founders with the world’s best people and to fund their companies from the idea stage to meaningful clinical data. We spoke with Allison DeAngelis about our new $380M Pro Rata Series A Fund, which will support our portfolio companies through the clinic. Read more from STAT.

At Curie.Bio, we believe the single greatest unlock of innovation in biotech over the next decade will come from giving founders the support and access they need to build successful companies. Today, we are excited to announce the closing of our $380M Pro Rata Series A Fund, bringing the total funds we have raised to nearly $1B. This will enable us to continue investing in successful early-stage therapeutics companies on their path to generating meaningful clinical data. Read more here. https://lnkd.in/emKuFu_p #FreeTheFounders

Imagine having instant access to some of the world's best drug hunters and biotech operators to help you maximize your company's success. Curie.Bio brings that team to you. Our CSO Partner Team has brought more than 150 drugs into the clinic with over 30 approvals. We know what it takes to turn therapeutic concepts into drugs that make a meaningful impact on patients and generate enduring value for a company. Get a glimpse into your copilots and the expertise they bring to your company below.  

World Class Drug Hunters + Capital Efficient Progress = Founders Win That's Curie.Bio. We bring the most exciting therapeutic ideas to clinical proof of concept in just two financing rounds, meaning founders own more of their company at the end. We do that through a unique combination of investing and drug discovery copiloting in early-stage therapeutics companies. We share more about what we're all about below. 

Founders often get crushed by dilution when raising a Series A. Dilution is a product of capital raised and company valuation. Curie.Bio helps founders minimize dilution by maximizing progress with less capital. By reaching critical milestones on blockbuster TPPs, you can raise more capital at a much higher valuation. Last fall, our first portfolio company, Forward Therapeutics, Inc., raised a $50M Series A to generate clinic data. A recent Oppenheimer report revealed this raise was the BIGGEST valuation step up compared to all other therapeutics companies that raised a Series A in the last 12 months. The best part? The founders retained significant ownership in their company. That's the power of the Curie.Bio model. That's how we #freethefounders. If you have an exciting therapeutic idea, we'd love to collaborate. Contact our team or visit our website. https://lnkd.in/e4NWnqwF

Drug hunters hunt for drugs. We hunt for the best drug hunters. In that pursuit, we're excited to announce that Chris Smith has joined our CSO Partner Team as a copilot for founders of our portfolio companies. As a medicinal chemist at Mirati, Takeda, Eli Lilly, and Pfizer, Chris has contributed to seven clinical-stage molecules in oncology, sexual health, and autoimmune. https://lnkd.in/eApeMHu9

Curie.Bio is proud to expand our expertise in cytokines and our presence in Seattle through the hiring of Heather Arnett to our CSO Partner Team as a copilot for founders of our portfolio companies. Heather brings two decades of biologics drug discovery experience with contributions to seven clinical-stage drugs, two of which are approved (TEZSPIRE® and POTELIGEO®). https://lnkd.in/eu7FRz-U

No one understands the needs of a biotech founder better than someone who just went through their own founder journey. Curie.Bio is proud to welcome Leah Sibener, Ph.D. to the CSO Partner Team as a copilot for founders. Leah co-founded and built 3T Biosciences, a therapeutics company spinout leveraging her Ph.D. work in Chris Garcia's lab at Stanford. To learn more about Leah and how she'll support founders, read her bio at the link below. https://lnkd.in/e_kzC6XR

Join us at the 2024 Convergence Forum, where Curie.Bio CEO Zach Weinberg will be speaking alongside Steve Pagliuca (Arena Bioworks) and Daphne Zohar (PureTech Health) to discuss new models for launching therapeutics companies. Meeting agenda → https://lnkd.in/eqtP66Au

We're thrilled to welcome Dallas Jones to our CSO Partner Team as a copilot for the founders of our portfolio companies. Dallas provides a wealth of experience after leading multiple programs from early-stage drug discovery through clinical development in Immunology and Neuroscience through his experience at Merck and Abide Therapeutics. He also supported the launch of multiple Series A therapeutics companies at Inception Sciences, the discovery engine of Versant Ventures. To learn more about Dallas and how he'll support founders, read his bio at the link below. https://lnkd.in/eDzkV-4q